Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent
Reporter: Aviva Lev-Ari, PhD, RN
Next stop, filing for approval. The Medicines Company has said it plans to submit inclisiran for FDA review by the end of 2019 and EMA review in the first quarter of 2020. If the drug’s approved it’ll be the third anti-PCSK9 behind mAbs Repatha and Praluent, and could try to compete on price to gain market share.
The company’s been very careful not to disclose its pricing plans for inclisiran, said ORION-10 principal investigator Dr. Scott Wright, professor and cardiologist at the Mayo Clinic. But, Wright said, The Medicines Co. and other companies he advises on clinical trial design “have learned the lesson from the sponsors of the monoclonal antibodies [against PCSK9], they’re not going to come in and price a drug that’s out of proportion to what the market will bear.”
Because the anti-PCSK9 mAbs were initially priced beyond what patients and insurers were willing to pay, “now most of the physicians that I meet have a resistance to using them just because they’re fearful about the pre-approval process” with insurers, said Wright. “They’re much easier to get approved and paid for today than they’ve ever been, but that message is not out in the medical community yet.”
SOURCE
From: “STAT: AHA in 30 Seconds” <newsletter@statnews.com>
Reply-To: “STAT: AHA in 30 Seconds” <newsletter@statnews.com>
Date: Monday, November 18, 2019 at 2:59 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Interim look at Amarin data, an inclisiran update, & Philly’s giant heart
Leave a Reply